Gerd Zettlmeissl
Président chez MEDIGENE AG
Profil
Gerd Zettlmeissl is currently the Chairman-Supervisory Board at MediGene AG since 2019, Chairman-Supervisory Board at MSD Wellcome Trust Hilleman Laboratories Pvt Ltd.
since 2013, and Director at Aeras Global TB Vaccine Foundation since 2011.
Previously, he served as Chairman-Management Board at Intercell AG from 2010 to 2011, Chairman at GlycoVaxyn AG from 2013 to 2015, Chairman at DMS Imaging SA from 2017 to 2018, and Chairman-Supervisory Board at Themis Bioscience GmbH from 2015 to 2020.
He also held positions at Chiron Behring & Co., Helmholtz-Zentrum für Infektionsforschung GmbH, and Chiron Corp.
Dr. Zettlmeissl holds a doctorate degree from the University of Regensburg.
Postes actifs de Gerd Zettlmeissl
| Sociétés | Poste | Début |
|---|---|---|
| MEDIGENE AG | Président | 22/05/2019 |
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Directeur/Membre du Conseil | 14/11/2011 |
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd.
 MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. BiotechnologyHealth Technology MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. develops and researches vaccines. The joint venture company is based in Gurgaon, India. The company was founded in 2009. Raman Rao has been the CEO of the Indian company since 2020. | Président | 01/01/2013 |
Anciens postes connus de Gerd Zettlmeissl
| Sociétés | Poste | Fin |
|---|---|---|
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Président | 01/01/2020 |
| EUROPEAN MEDICAL SOLUTIONS | Président | 18/12/2018 |
GlycoVaxyn AG
 GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Président | 01/01/2015 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Directeur Général | 10/05/2011 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Gerd Zettlmeissl
| University of Regensburg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| EUROPEAN MEDICAL SOLUTIONS | Health Technology |
| MEDIGENE AG | Health Technology |
| Entreprise privées | 8 |
|---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Helmholtz-Zentrum für Infektionsforschung GmbH
 Helmholtz-Zentrum für Infektionsforschung GmbH BiotechnologyHealth Technology Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany. | Health Technology |
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
GlycoVaxyn AG
GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland. | Health Technology |
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Health Technology |
Chiron Behring & Co.
 Chiron Behring & Co. Medical DistributorsDistribution Services Part of Novartis AG, Chiron Behring & Co. is a German company that supplies and develops new vaccine products for adults and children. The company is based in Marburg, Germany. Chiron Behring was acquired by Chiron Corp. from Hoechst AG on April 01, 1998 for $111.90 million. | Distribution Services |
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd.
MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. BiotechnologyHealth Technology MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. develops and researches vaccines. The joint venture company is based in Gurgaon, India. The company was founded in 2009. Raman Rao has been the CEO of the Indian company since 2020. | Health Technology |
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
